In the past week, PGEN stock has gone down by -16.09%, with a monthly gain of 21.94% and a quarterly surge of 102.58%. The volatility ratio for the week is 9.41%, and the volatility levels for the last 30 days are 10.37% for Precigen Inc The simple moving average for the past 20 days is 1.48% for PGEN’s stock, with a 40.26% simple moving average for the past 200 days.
Is It Worth Investing in Precigen Inc (NASDAQ: PGEN) Right Now?
The stock has a 36-month beta value of 1.58. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PGEN is 162.74M, and at present, short sellers hold a 11.70% of that float. On February 25, 2025, the average trading volume of PGEN was 1.89M shares.
PGEN) stock’s latest price update
The stock price of Precigen Inc (NASDAQ: PGEN) has dropped by -3.14 compared to previous close of 1.75. Despite this, the company has seen a fall of -16.09% in its stock price over the last five trading days. prnewswire.com reported 2025-02-25 that – Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions – – If approved, PRGN-2012 would be the first and only available FDA-approved therapy for eligible patients with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – GERMANTOWN, Md., Feb. 25, 2025 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the US Food and Drug Administration (FDA) has accepted the company’s biologics license application (BLA) for PRGN-2012 (nonproprietary name: zopapogene imadenovec † ), an investigational AdenoVerse ® gene therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at 34.04% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.89% of loss for the given period.
Volatility was left at 10.37%, however, over the last 30 days, the volatility rate increased by 9.41%, as shares surge +36.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +126.60% upper at present.
During the last 5 trading sessions, PGEN fell by -12.38%, which changed the moving average for the period of 200-days by +28.26% in comparison to the 20-day moving average, which settled at $1.6740. In addition, Precigen Inc saw 51.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from Perez Jeffrey Thomas, who purchase 58,823 shares at the price of $0.85 back on Aug 09 ’24. After this action, Perez Jeffrey Thomas now owns 743,097 shares of Precigen Inc, valued at $50,000 using the latest closing price.
KIRK RANDAL J, the Director of Precigen Inc, purchase 23,529,411 shares at $0.85 during a trade that took place back on Aug 09 ’24, which means that KIRK RANDAL J is holding 64,547,214 shares at $19,999,999 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -32.78 for the present operating margin
- -0.63 for the gross margin
The net margin for Precigen Inc stands at -35.22. The total capital return value is set at -2.09. Equity return is now at value -137.46, with -101.81 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.17. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -9992.69.
Currently, EBITDA for the company is -89.23 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 123.43. The receivables turnover for the company is 5.44for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Precigen Inc (PGEN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
